Beyond Tax Benefits: Portfolio Opportunities In A Pfizer-Allergan Deal
This article was originally published in Scrip
Executive Summary
Pfizer Inc. and Allergan plc continue to be in closed-door discussions regarding a potential merger that could significantly cut Pfizer's tax rate due to Allergan's Irish corporate base, but Allergan also has several commercial products and research-stage assets that could fill gaps in Pfizer's portfolio.
You may also be interested in...
Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter
Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Need a specific report? 1000+ reports available
Buy Reports